Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students
Recruiting
Phase 4
Interventional Study
HPV Vaccine
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 15 – 17
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 300 (estimated)
- Sponsor
- Canadian Immunization Research Network · Research network
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Since the 2019-2020 school year, the province of Quebec (Canada) has been administering one dose of nonavalent (9vHPV) vaccine to students of all genders in Grade 4 of elementary school through the school-based program.
Little data on the immunogenicity (antibody production) and long-term efficacy of a single dose of the vaccine are available, particularly in boys.
The primary objective of this …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Have received a single dose of 9vHPV vaccine at ages 9-11 during the school year 2019-2020;
* Not have received any other HPV vaccine doses;
* Be able to consent to the study.
Exclusion Criteria:
* Immunosuppressed (at recruitment or when immunized).
Contacts